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a b s t r a c t
Although the main reservoir of Candida spp. is believed to be the buccal mucosa, these
microorganisms can coaggregate with bacteria in subgingival biofilm and adhere to epithe-
lial cells. The treatment of periodontal disease includes scaling and root planning (SRP)
associated with proper oral hygiene. However, some patients may have negative responses
to different therapeutic procedures, with a continuous loss of insertion, so the use of
antimicrobials is needed as an adjuvant to SRP treatment. The use of a broad-spectrum
antibiotic, such as tetracycline and metronidazole, as an aid in periodontal treatment has
also been a factor for the development of superinfections by resistant bacteria and Candida
species, even in patients with HIV. In the dental practice, the most commonly used
antifungals are nystatin and fluconazole. However, the introduction of new drugs like
the next generation of azoles is essential before the onset of emergent species in periodontal
disease. Plants are good options for obtaining a wide variety of drugs. This alternative could
benefit a large population that uses plants as a first treatment option. Plants have been used
in medicine for a long time and are extensively used in folk medicine, because they
represent an economic alternative, are easily accessible and are applicable to various
diseases. Herein, we briefly review the literature pertaining the presence of Candida sp.
in periodontal pockets, the conventional antifungal resistance and new therapies that
include natural antifungal agents are reviewed.
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Candida species are commensal yeasts in healthy humans and
may cause systemic infection under immunocompromised
situations due to its high adaptability to different host miches.
It was suggested that when C. albicans accessed the periodon-
tal tissues, they may be harmed by the production of
metabolites by these yeasts.1
The periodontal disease is a chronic infection that affects
the gingiva and bone that supports the teeth. This chronic
inflammatory disease results from the response to micro-
rganisms in dental biofilm and may remain confined to the
gingival tissues with minimal tissue alterations; alternatively,
this disease may progress to extreme periodontal destruction
with the loss of attachment and alveolar bone. In addition to
the presence of periodontal pathogens; such as Porphyromonas
gingivalis, Aggregatibacter actinomycetemcomitans and Tannerella
forsythia; genetic and environmental factors seem to increase
the susceptibility of some individuals in developing this severe
inflammatory disease.2 Therefore, there is general support for
this concept of periodontal disease. It is also well recognized
that the presence of just pathogenic bacteria is insufficient to
cause periodontitis. Progression of this disease occurs due to a
combination of factors, including the presence of period-
ontopathogenic microorganisms, high levels of pro-inflam-
matory cytokines, matrix metalloproteinases (MMPs),
prostaglandin E2 (PGE2), low levels of anti-inflammatory
cytokines including interleukin-10 (IL-10), transforming
growth factor (TGF-b) and tissue inhibitors of MMPs (TIMPs).3,4
However most microorganisms found in subgingival biofilm is
commensal, or also occurs in individuals with a healthy
periodontium that is in equilibrium with the host. Thus,
episodes of disease resulting from deficiencies in the ability of
the host defence to fight the bacterial biofilm, changes the
quantitative or qualitative subgingival microbiota.5,6
Periodontal diseases are classified as either gingivitis or
periodontitis. Gingivitis is an infection associated with biofilm,
characterized by an occurrence of reversible inflammatory
phenomena limited to the gingival tissues and not affecting
the supporting periodontal tissues. Clinical signs of gingivitis
range from oedema, abnormal staining of normal gums,Table 1 – Data on resistance of Candida spp. isolated from sub
Isolates % Azoles resistance %
C. albicans 4.2 0
Non-C. albicans 6.25 6
C. albicans 3.3 0
Non-C. albicans 17 N
C. albicans 0 N
Non-C. albicans 42.8 7
C. albicans 3.6 7
Table 2 – In vitro antifungal activity of natural extracts on Can
AC MP SC 
C. albicans 15 7 1 
Non-C. albicans 15–30 1–7 1 
AC, Arrabidae chica; MP, Mentha piperita; SC, Syzygium cumini; TA, Tabebuiaunusual redness, and loss of normal contour of gingival.7
Periodontitis is defined as an inflammatory disease that
involves the tissues of dental support, leading to irreversible
alveolar bone resorption and destruction of the collagen fibres
of the periodontal ligament. The severity and progression of
this disease is influenced by local or systemic conditions or
from both a combination of both.8 Local factors are associated
with poor oral hygiene, the presence of cavities, and the
presence of dentures that can cause plaque accumulation.
Systemic factors are related to the metabolism of the host,
immunosuppressive therapy, malnutrition, diabetes mellitus
and HIV infection (Tables 1 and 2).7
A complex microbiota can be found in the periodontal
pocket affected by the disease, where approximately 500
species of bacteria can occur, amongst them are A. actinomy-
cetemcomitans, and other microorganisms such as Entamoeba
sp., virus, some Enterobacteriaceae, Pseudomonas sp., and
Candida species.9–12 This fact has led to an extensive study of
microbiological samples from periodontal lesions, especially
in cases where there is a poor response to conventional
treatment. In many of these cases, fungi have been found
colonizing the periodontal pockets. There are several reports
associating the occurrence of severe periodontitis with the
isolation of Candida species from periodontal lesions.13,14
However, the clinical significance of these observations and
the role of microorganisms in the pathogenesis of periodontal
diseases are not well understood. Many scientific investiga-
tions have been performed in order to extend the knowledge in
this area.15 However, the presence of fungi in periodontal
pockets has not yet received the necessary focus to under-
stand its role as periodontal pathogens, although they have
been recognized for their ability to adhere to the epithelium,
express virulence factors and induce inflammatory reac-
tions.16
The treatment of periodontal disease includes scaling and
root planning (SRP) associated with proper oral hygiene.
However, some patients may have negative responses to
different therapeutic procedures, with a attachment loss, so
the use of antimicrobials is needed as an adjuvant to SRP
treatment.17 The use of a broad-spectrum antibiotic, such as
tetracycline and metronidazole, as an aid in periodontal
treatment has also been a factor for the development ofgingival sites.
 Amphotericin resistance References
 Waltimo et al.64
.25 Ito et al.62
 Ito et al.62
o studied Jewtuchowicz et al.56
o studied Jewtuchowicz et al.56
1.4 Furletti et al.61
2.9 Furletti et al.61
dida species (mg/mL), according Ho¨ fling et al.94
TA RO PG Fluconazole
3 1 3 32
1–15 1–7 1–3 32–64
 avellanedae; RO, Rosmarinus officinalis; PG, Punica granatum.
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The use of a broad-spectrum antibiotic, such as tetracycline
and metronidazole, as an aid in periodontal treatment
associated with SRP has been recommended for the treatment
of periodontal disease.18,19
Metronidazole and amoxicillin antibiotics to be seem
indicated for the treatment of periodontal infections. Lotufo
et al.,20 performed antimicrobial susceptibility tests in vitro for
105 strains of anaerobic bacteria isolated from patients with
periodontitis. According to the results, the antimicrobial
metronidazole was more action on the organism studied.
None of the isolates showed resistance to metronidazole.
Amoxicillin also showed good results, with approximately 94%
of strains sensitive to this drug.
In the dental practice, the most commonly used anti-
fungals are nystatin and fluconazole. It is believed that the
presence of C. albicans in subgingival sites is in the form of
biofilms, which could explain the resistance to antifungal
therapy.
Plants are good options for obtaining a wide variety of
drugs.21 This alternative could benefit a large population that
uses plants as a first treatment option.22 Plants have been used
in medicine for a long time and are extensively used in folk
medicine, because they represent an economic alternative, are
easily accessible and are applicable to various diseases.23
Therefore, these constitute an excellent alternative in the
search for substances that can be used to develop new
antifungal drugs.24 It is necessary to seek new antifungal
agents that are fungicides, which cause disruption or
destruction of biofilms, which are effective in isolates that
express resistance using several molecular mechanisms and
which are not toxic.
In the present report, the literature on the presence of
Candida spp. in periodontal pockets, the conventional antifun-
gal resistance and new therapies that include natural
antifungal agents are reviewed.
2. Colonization of the oral cavity by Candida
spp.
Based on their prevalence in healthy and asymptomatic
populations, the isolation of Candida spp. from the oral cavity
does not necessarily imply an infection.25 Many studies have
shown that approximately half of the healthy adult population
carries yeasts in the oral mucosa, however, the prevalence has
been found to vary amongst different population groups.25,26
Several different groups present levels of oral colonization by
yeasts larger than the average population in general, with
these groups being known at-risk populations.27 Studies
report a higher prevalence of Candida species in patients with
Down’s syndrome, in individuals with salivary gland hypo-
function, decreased flow or salivary pH and diabetes mellitus.
These conditions seem to alter the oral environment and
promote colonization by these and other species of opportu-
nistic pathogens.28 The occurrence of these fungi has also
been reported in HIV-positive patients, with rates of infection
that are higher than in other at-risk populations.29 The
increasing proportion of these fungi suggests a deficient
immune response associated with the progression of viralinfection in HIV-infected individuals, which could be a
predictive factor for the development of candidiasis.28 The
occurrence of yeast is also common in patients with advanced
cancer with oral candidiasis a serious medical condition
amongst these patients. Epidemiological studies are therefore
needed on the distribution and virulence potential of these
yeasts in different population groups, addressing risk factors
and developing strategies for the control and prevention of
infections.27,30,31 Yeasts are found colonizing various sites in
the oral cavity (lingual, palate, tonsils, mucosa of the lips and
cheeks, caries, periodontic and endodontic lesions).32–35
Siqueira and Roˆ c¸as35 found C. albicans species associated with
bacteria in teeth with periodontal pockets around areas of root
exposure. For those authors, resistance to intra canal drugs,
and the ability of these yeasts to colonize and invade the
dentine tubules, may explain the presence of yeast in
persistent endodontic infections.
The use of a prosthesis is another factor that may favour
colonization of the oral cavity by Candida spp.36 with a report
indicating that the microbiota between a prosthesis and palate
mucosa has a composition similar to dental biofilm, except for
a greater proportion of Candida species, a fact related to the
development of candidiasis on the mucosa of the palate.
Kleinegger et al.37 concluded that a number of natural
barriers existed in the mucosal surfaces and body fluids;
preventing the colonization in healthy individuals. These
barriers are more or less effective, depending on factors
related to age, gender, smoking, diet, drugs and the host
immune status. This explains the fact that not all individuals
harbour Candida spp.
Saliva helps maintain oral health, provides a buffering
capacity and provides lubrication of the mucous membranes;
therefore, qualitative and quantitative changes in saliva
inevitably affect the physiology, defence mechanisms and
microbial ecology of the mouth.38 Lactoferrin and lysozyme
are two proteins in the innate immune response present in
saliva and exert an antifungal modulating effect on the
implantation of species of Candida in the oral cavity.39 Other
important proteins in human saliva that have a cytotoxic
action on bacteria and fungi are the histatins, estaterins,
lactoperoxidase and calprotectin.37 According to Lin et al.,40
when there is a decrease when the concentration of salivary
histatins, dysfunction of these proteins occurs and candidiasis
tends to manifest. HIV-infected individuals show a reduction
in salivary flow and an anti Candida activity of saliva and are
often suffering from oropharyngeal candidiasis. For those
authors, the saliva contained mucins and aggregated IgA,
histatin, lactoferrin and lysozyme, which remained focused
on mucosal surfaces and exerted an antimicrobial effect.41 C
albicans is able to connect to several species of streptococci (S.
oralis, S. sanguinis, S. gordonii, and Fusobacterium) through
recognition receptor polysaccharides in the bacterial cell
surface. F. nucleatum is an anaerobic gram-negative bacillus
commonly associated with periodontal lesions and isolated
from subgingival biofilm.41,42 Biofilm formation has been
considered an important strategy for microbial survival and
proliferation in the oral environment. The complex structure
of a biofilm allows microorganisms to offer protection against
the antimicrobial mechanisms of saliva and hinder the action
of antimicrobial agents.43 It is believed that most of the
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formation, and recognition of the biofilm features may help in
developing therapeutic strategies for these infections.44 For
the current author, the biofilms formed by C. albicans and C.
dubliniensis have several features in common with bacterial
biofilms, including the structural heterogeneity and reduced
susceptibility to antimicrobial agents when mature. These
biofilms consist of a mixture of yeast and filamentous cells
embedded in a matrix of exopolymers, which serves as a
reservoir for the release of infective organisms in the oral
cavity. This can allow the survival of yeast in their ecological
niches during infectious episodes, which, according to
Ramage et al.,44 has important clinical, treatment and
prevention implications. Thus, the biofilms containing mostly
C. albicans could be implicated, not only in mucosal candidosis,
but also in the development of caries45 and in the pathogenesis
of periodontal disease.46,47
2.1. Candida spp. in subgingival sites
Candida species possess virulence factors relevant in the
pathogenesis of periodontal disease, such as the ability to
adhere to the epithelium and invade the gingival connective
tissue, the ability to inhibit the function of polymorphonuclear
neutrophils, and produce enzymes such as collagenases and
proteinases which degrade immunoglobulins.32,47–49 Accord-
ing Ha¨gewald et al.,33 microorganisms that are capable of
degrading IgA may acquire a selective advantage in the
colonization of oral surfaces. Those authors believe that the
proteolysis of immunoglobulins facilitates the penetration
and spread of potentially toxic substances or antigens released
by the subgingival microbiota. That process could perpetuate
inflammatory changes associated with destructive periodon-
tal diseases. The periodontal alterations have been considered
a result of an exacerbated immune response against the host
tissues, with changes in cellular and humoral immune
responses that allow different species, such as Candida, to
colonize the subgingival environment.50 The detection of fungi
in the subgingival region has been suggested to contribute to
the pathogenesis of periodontal disease and to increase the
possibility of candidiasis, mainly in cases of immune depres-
sion.32,46 However, the role of yeasts, mainly Candida albicans,
in chronic periodontitis is yet unclear.51
Isolation of subgingival Candida species has been described
by many authors in different manifestations of periodontal
disease, for example, in cases of aggressive periodontitis,33
chronic periodontitis,9,49 in periodontal pockets of smokers,52
diabetics,9,53 myelosuppressed patients54 and in perimplanti-
tis. Certain Candida species are considered to be commensal
organisms within the oral cavity. Indeed, the prevalence of
oral yeast in the general population is about 34%.54 In 24
patients with acute periodontal infection and chemotherapy-
induced myelosuppression, microorganisms were detected in
high concentrations in subgingival pockets with a predomi-
nance of Staphylococcus epidermidis, C. albicans, S. aureus, and
Pseudomonas aeruginosa, with combinations of these detected
in some patients.54
Raber-Durlacher et al.,55 addressed the pathogenesis of
periodontal disease and the possibility of transmission of
systemic subgingival microorganisms in patients with cancertreated with chemotherapy. Those authors reported that oral
infections are larger problems, mainly because there is a
higher risk of infections spread from microorganisms of the
mouth during the neutropenia occurring after chemotherapy.
Thus, the inflamed periodontal tissues may act as a focus of
infection, bringing significant morbidity and, in some cases
can become life-threatening. Still, there is evidence that
gingivitis and periodontitis are associated with fever and
sepsis in these patients, because the ulcerated epithelium of
periodontal pockets may serve as a route of entry of
microorganisms into the bloodstream, and the propagation
of systemic endotoxins and other inflammatory mediators.
Jewtuchowicz et al.56 identified different species of yeasts
using conventional mycological methods and specific poly-
merase chain reaction (PCR) assays from samples at sites of
periodontal disease isolated from immunocompromised
patients, such as those with advanced HIV infection. Amongst
76 fungal organisms isolated, C. dubliniensis comprised 10.5% of
total, which corresponded to 4.4% of patients studied. C.
albicans was the most frequently isolated species of yeast.
However, Sardi et al.9 detected some species of Candida,
using the PCR method, in higher quantities in diabetic patients
when compared with non-diabetic patients with chronic
periodontal disease. C. albicans were found in 57.3%, C.
dubliniensis in 75.6%, C. tropicalis in 15.85% and C. glabrata in
4.87% of the periodontal pockets of diabetic patients. For non-
diabetic patients, 19.17% and 13.69% of the periodontal sites
presented C. albicans and C. dubliniensis, respectively. C.
tropicalis and C. glabrata were not found in the periodontal
pocket of non-diabetic patients. Urzu´ a et al.57 analysed the
composition of the yeast microbiota present in the mucosal
and subgingival sites of healthy individuals and patients with
aggressive and chronic periodontitis, using phenotypic and
genotypic methods. Despite the varied profiles of the species
present in the mucosa of the three groups analysed, only C.
albicans and C. dubliniensis were capable of colonizing the
periodontal pockets in patients with chronic periodontitis,
whilst only C. albicans was identified in the subgingival sites of
healthy individuals and patients with aggressive periodontitis.
Periodontal conditions were studied in two cross-sectional
studies of adult, insulin-dependent diabetics and age- and
sex-matched controls. In one study, 154 diabetics and 77
control patients participated. In the other study, 82 diabetics
and 99 control patients took part. The number of individuals
exhibiting severe periodontal disease was superior in the
diabetic group than in the control group.58 However, a
relationship between diabetes mellitus, periodontal disease
and the presence of Candida spp was not found. Additionally,
the moderately increased glucose content of diabetic patients
did not result in higher mean numbers of C. albicans. Similar
results were obtained by Yuan et al.,53 who verified that there
were no significant differences in the prevalence of the some
microorganisms, including C. albicans, between the diabetic
and the non-diabetic groups.
Ja¨rvensivu et al.47 investigated the occurrence and extent of
penetration of C. albicans in periodontal tissues of patients
with chronic periodontitis in gingival tissue specimens
collected during periodontal surgery. These specimens were
examined by immunohistochemistry using specific antibodies
to C. albicans; the presence of hyphae penetrating the
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that an environmental change may have promoted the
germination of hyphae that have a greater capacity to adhere
to host tissues, and that the crevicular fluid and periodontal
pockets formed a favourable environment for germination of
these morphological structures. C. albicans could then play a
role in the infrastructure of the subgingival biofilm, and their
adherence to the periodontal tissues, since they are more
resistant to immune mechanisms that most microorganisms
present at that location.
Barros et al.49 studied Candida species in the periodontal
pockets of chronic periodontitis patients without systemic
changes; the most prevalent species was albicans with only one
isolate of C. dubliniensis.
Cuesta et al.59 analysed patients with periodontal disease
and found 25.6% of Candida species with C. albicans as the most
prevalent at 76.2%.
However, one of the factors related to a lack of response to
periodontal therapy is the failure to eliminate the reservoirs of
infectious organisms, or the appearance of superinfecting
pathogens such as Enterobacteriaceae, Pseudomonas sp., Staphy-
lococcus sp. and Candida species.60 The treatment of periodon-
tal disease includes SRP associated with proper oral hygiene. It
has been shown that these procedures are essential for
successful periodontal therapy, reducing pocket depth and
eliminating periodontal microbiota.60 However, some patients
may have negative responses to different therapeutic proce-
dures, so the use of antimicrobials is needed as an adjuvant
treatment SRP.17 The use of a broad-spectrum antibiotic, such
as tetracycline or metronidazole, as an aid in periodontal
treatment has also been a factor for the development of
superinfection by resistant bacteria and Candida ecies.18,19 The
use of an antifungal is needed but many of these Candida spp.
present in periodontal pockets are resistant to existing drugs,
necessitating the search for natural alternatives.56,61–64
2.2. Resistance of yeasts to synthetic antifungals
In the treatment of fungal infections, oral antifungal drugs are
administered. The most common antifungal medications are
the azoles. However, this treatment becomes quite limited due
to resistance problems and significant efficacy of drugs.
Currently, the therapeutic practice covers a limited number
of antifungals such as amphotericin B, fluconazole, itracona-
zole and more recently, voriconazole, although others also
show promising results, such as posaconazole, ravuconazole,
caspofungin and micafungin.65
The conventional treatment of periodontal disease is
usually effective, except in cases of proven resistance to
isolates. Some studies show the inefficiency of therapy
depending on the selection of populations of the genus
Candida. In these cases, the isolate of Candida spp. reports of
resistance or treatment failure are attributed to the difficult
access of antifungal drugs in these sites.60
In the dental practice, the most commonly used anti-
fungals are nystatin and fluconazole.63,65,66 Antifungal agents
such as amphotericin B, 5-fluorocytosine, voriconazole and
terbinafine are not usually employed in the treatment of oral
candidiasis; however, they also deserve attention. Although
these antifungals are available only for systemic use and arerecommended for the treatment of disseminated infections,
the determination of a minimum inhibitory concentration
with respect to isolates from the oral cavity of patients with
immunosuppression is important, especially in cases of
periodontitis, for obtaining epidemiological data and the
possibility of the oral cavity being the original focus of
disseminated fungal infections.62,67
Waltimo et al.,64 whilst evaluating the antifungal suscepti-
bility amongst isolates of C. albicans in periodontal pockets,
showed that 100% of these isolates were sensitive to
amphotericin B and 5-flucytosine.
However, sensitivity to azole antifungals was shown to be
variable. This fact corroborates with recent data that indicates
an increasing azole resistance amongst Candida species,
suggesting that the oral cavity, seems to be a major factor
in the increased frequency of C. albicans and other non-
albicans.68–70 Dumitru et al.71 studied isolates of C. albicans
under conditions of hypoxia and found strains resistant to
amphotericin B and four azole antifungal classes, thus
concluding that these anaerobic yeasts were more resistant
to antifungal drugs; thus explaining the resistance of biofilms
of C. albicans to several antifungal drugs. Perkholfer et al.72
evaluated anidulafungin and voriconazole alone and in
combination against conidia and hyphae under conditions
of hypoxia in isolates of Aspergillus and observed that
anidulafungin exhibited excellent activity against conidia
and hyphae of Aspergillus sp. The reading of the MIC for
anidulafungin was optimal under hypoxic conditions. Results
presented by Furletti et al.61 showed that C. albicans isolated
from periodontal pockets were resistant to amphotericin B
and sensitive to fluconazole. This result shows that there may
be difficulty in the infusion of the drug in the periodontal space
or resistant strains may be due to overexpression of efflux
genes.
Jewtuchowicz et al.56 studied isolates of C. albicans and C.
dubliniensis in patients with and without periodontitis and
consistently found that only one isolate was resistant to
fluconazole and voriconazole. C. albicans appears to be
contributing to bacterial biofilm formation on these structures
and hindering the penetration of certain antimicrobial
drugs.47 Still, for these studies, C. albicans was found typically
in the outer layers of the biofilm, and seemed to act according
as expected, as a barrier protecting the microorganisms of the
deep interior from the action of immune mechanisms, aiding
the resistance of the subgingival microbiota in the face of host
defences, and contributing to the persistence of inflammation
in adjacent tissues. Biofilms of C. albicans were highly resistant
to the clinical action of antifungal and antimicrobial agents,
including amphotericin B, chlorhexidine, nystatin and flucon-
azole.72 In that work, it was demonstrated that as the C.
albicans biofilms matured, there was concurrent acquisition
and increased resistance of yeast cells in relation to the
antimicrobials. The prophylactic use of fluconazole in low
doses has been recommended for preventing fungal infections
in immunocompromised patients. However, this has led to the
selection of yeast microbes that are resistant to this antifungal
agent, causing this resistance to appear in non-albicans
species such as C. glabrata and C. krusei, in addition to having
the sensitive C albicans be replaced by another of the same
species that is fluconazole-resistant and to become resistant
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point, the most important feature of biofilm growth is the
resistance to antimicrobial agents exhibited by organisms.75,76
Studies have shown that biofilms formed by Candida species
were more resistant to major antifungal agents used in the
clinic, such as amphotericin B, fluconazole, itraconazole, and
ketoconazole.77 New azoles, like voriconazole and ravucona-
zol, were also ineffective against biofilms.52,78–81 The intrinsic
resistance of Candida species biofilms to fluconazole, an agent
commonly used for antifungal treatment due to greater
resistance to amphotericin B, has been reported.81 However,
therapeutic levels of echinocandins may inhibit the metabolic
activities in C. parapsilosis biofilms,82–84 whilst lipid formula-
tions of amphotericin B also showed activity against the same
biofilms.77,81 The progression of drug resistance by Candida
biofilms has been associated with the parallel increase of the
maturation process.85 Furthermore, some researchers have
also shown that biofilms of Candida developed statically with
the presence of minimal matrix and exhibited the same level
of resistance to drugs (fluconazole and amphotericin B) as the
cells grown in a lab and exhibiting large amounts of matrix.86
Therefore, there are many controversies regarding the
mechanisms of resistance to antifungal agents. In addition
to the reduced sensitivity described by some authors in
periodontal disease, it is believed that the presence of C.
albicans in subgingival sites allows the formation of biofilms,
which could explain the resistance to antifungal therapy.
Several molecular mechanisms of resistance to antifungal
agents in C. albicans have been described, highlighting in
particular: the increased efflux of antifungal agents due to the
over expression of efflux genes, CDR1, CDR2 (the family of ABC
membrane transport proteins – ATP Binding Cassette)87 and
MDR1 (family protein Major Facilitator); the amino acid
substitutions in Erg11p enzyme (lanosterol 14-a desmetilase),
encoded by the gene ERG11. This gene in turn can be expressed
in cells with super changes in several of the biosynthetic
pathways for ergosterol, as no formation of the toxic
metabolite 14-a metilergosta-8, 24-diene-3 b, a 6-diol metabo-
lite from 14 a-metilfecosterol due to changes in the ERG3
gene.87–89 Considering it essential to understand how genes
are regulated, CDR1 and CDR2 and other genes are often co-
regulated and are over-expressed simultaneously, therefore it
is believed that there is a chance of mutations in genes
regulating this expression.90
2.3. Search of new natural antifungal drugs
A search for new antifungal agents and the characterization of
new targets which are more appropriate and efficient,
including the emergence of resistant strains, has been
proposed.91 An ideal antifungal agent should have broad-
spectrum antifungal activity and would not cause toxicity to
the host.62 Plants are good options for obtaining a wide variety
of drugs.21 Plants have been used in medicine for a long time
and are extensively used in folk medicine because they
represent an economic alternative, are easily accessible and
would be applicable to various pathologies.23 These constitute
an excellent alternative for substances that can be used in the
formulation of new antifungal agents.24 The antifungal
compounds of the plants assayed are not well known;however, the presence of flavonoids and terpenes and a
certain degree of lipophilicity might determine toxicity by the
interactions with the membrane constituents and their
arrangement. Since plants produce a variety of compounds
with antimicrobial properties, it is expected that screening
programmes for some under-represented targets, such as
antifungal activity, may yield candidate compounds for
developing new antimicrobial drugs.92 In addition, it is
expected that plant compounds showing targets sites other
than those currently used by antibiotics will be active against
drug-resistant microbial pathogens.93 Some extracts and
essential oils of medicinal plants with antifungal activity
were investigated by various researchers. Hofling et al.94
observed activity against strains of C. albicans (CBS-562), C.
dubliniensis (CBS-7987), C. parapsilosis (CBS-604), C. tropicalis
(CBS-94), C. guilliermondii (CBS-566), C. utilis (CBS-5609), C. krusei
(CBS-573), C. lusitaniae (B-060), C. glabrata (B-07), and C. rugosa
(B-12) with the extracts of Mentha piperita, Arrabidaea chica,
Rosmarinus officinalis, Tabebuia avellanedae, Syzygium cumini and
Punica granatum.
The yeast C. albicans, frequently associated with infections
in HIV (+) patients, was the most sensitive amongst all tested
microorganisms. Lippia sidoides essential oil showed an
appreciable amount of monoterpenes, a therapeutical poten-
tial that should not be ignored, and its phenolic compounds
(thymol and carvacrol) showed activity against oral patho-
gens.92 Duarte et al.95 investigated the essential oils and
ethanol extracts obtained from 35 medicinal plants for activity
against C. albicans and found that 13 of them showed
antifungal activity. The oil of Achillea millefolium, Mikania
glomerata and Stachys byzantina all had a strong activity against
C. albicans, whilst Aloysia triphylla, Anthemis nobilis, Cymbopogon
martini, Cyperus articulates, Cyperus rotundus, Lippia alba, Mentha
arvensis and M. piperita presented moderate activity. The
essential oil obtained from the leaves of Coriandrum sativum
showed antifungal activity against established biofilm and
planktonic cells of C. albicans isolated from periodontal
pockets.96 More et al.97 isolated C. albicans from periodontal
pockets and found that six of these (Annona senegalensis,
Englerophytum magalismontanum, Dicerocarym senecioides, Euclea
divinorum, Euclea natalensis, Solanum panduriforme and Parinari
curatellifolia), had an action on these organisms. Additionally,
they also indicated that eight species of plants from South
Africa had action against bacteria periodontipathogenic and
cytotoxicity in Vero cell lines. Scorzoni et al.22 indicated that
there was contact of the crude extracts derived from EtOAc
and EtOH Kielmeyera rubriflora, in addition to the commercial
drug fluconazole, against yeast C. krusei and subsequent
protein analysis by two dimensional electrophoresis. Several
changes in protein expression were observed and both
extracts were effective in inhibiting the expression of protein
C. krusei, suggesting the existence of specific targets. In
another study of Pterogyne nitens (Fabaceae), the antifungal
activity of compounds from the plant and the substance
purified pedalitina was able to inhibit the adhesion of
Cryptococcus neoformans to lung epithelial cells with similar
efficiency to conventional drugs. Additionally, changes were
observed in protein expression after contact with this
substance, showing a considerable activity in this yeast
proteome.98 Gregio et al.99 evaluated the antimicrobial
a r c h i v e s o f o r a l b i o l o g y 5 6 ( 2 0 1 1 ) 9 5 1 – 9 5 9 957properties of ginger extract against microorganisms found in
the oral cavity, such as Streptococcus mutans, Staphylococcus
aureus, E. coli and C. albicans, and observed action from the
extracts glycol and hidroalccolicos; however, the ethanol
extract and essential oil showed no antimicrobial activity
effective under some experimental conditions.
3. Conclusion
The interest in natural medicine has increased remarkably in
recent years as a result of side effects of conventional drugs, as
well as the emergence of antimicrobial resistance to available
drugs. Plants and their derivatives are therefore an important
alternative in the search for new drugs. For the development of
specific drugs for the treatment of periodontal disease caused
by coinfection by C. albicans, further studies should be
conducted on the proteins participating in biosynthetic
pathways of vital components for this agent.
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